Pharmacogenomics Technology Market to Grow with a CAGR of 8.45% through 2030

Rising Chronic Disease Prevalence and Rising Pharmaceutical Industry Investment are factors driving the Global Pharmacogenomics Technology Market in the forecast period 2026-2030

According to TechSci Research report, “Pharmacogenomics Technology Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Pharmacogenomics Technology Market stood at USD 7.60 Billion in 2024 and is anticipated to grow with a CAGR of 8.45% in the forecast period, 2026-2030.

Breakthroughs in next-generation sequencing (NGS), machine learning, and AI-enabled bioinformatics have significantly reduced both the cost and turnaround time for genomic analysis. These innovations have transformed pharmacogenomic testing into a more scalable, accurate, and clinically actionable tool, facilitating its rapid integration into both clinical diagnostics and research environments. The technological maturity of these platforms is a critical enabler of market growth, making PGx solutions more viable for large-scale deployment.

The healthcare industry is undergoing a structural shift from generalized treatment models to personalized, genomics-informed care delivery. Pharmacogenomics is central to this transformation, enabling the alignment of drug therapies with individual genetic profiles. This precision approach enhances treatment efficacy, minimizes adverse drug reactions, and improves patient adherence—three core performance metrics that directly impact health outcomes and cost-efficiency in care delivery. Global health authorities and regulatory bodies are progressively acknowledging the clinical utility of pharmacogenomics in optimizing therapeutic strategies and minimizing risk. New policies aimed at embedding PGx testing into clinical protocols—alongside the gradual expansion of insurance reimbursement models—are dismantling traditional access barriers. These regulatory tailwinds are not only legitimizing the technology but also incentivizing healthcare providers to adopt PGx testing as a standard clinical tool.

As clinical validation of pharmacogenomic testing continues to grow, education programs, guideline updates, and published outcomes data are improving stakeholder understanding and confidence. Physicians are becoming increasingly proficient in interpreting PGx data, and patients are more receptive to genetics-based treatment options. This cultural and clinical shift is translating into greater operational integration across hospitals, specialty clinics, and research centers. Pharmacogenomics is playing an increasingly strategic role in the development of companion diagnostics—particularly in therapeutic areas like oncology, neurology, and autoimmune diseases where drug response variability is high. As pharmaceutical pipelines become more focused on precision therapies, PGx testing is critical for identifying eligible patient populations, optimizing trial designs, and achieving regulatory success. This synergy is driving parallel growth in both diagnostic and therapeutic verticals.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Pharmacogenomics Technology Market”

The Global Pharmacogenomics Technology Market is segmented into Therapeutic area, technology and company.

Based on technology, The Polymerase Chain Reaction (PCR) segment is projected to experience rapid growth during the forecast period. PCR is a highly sensitive and specific technique for amplifying DNA. This precision is essential in pharmacogenomics, where researchers and clinicians need accurate and reliable data about genetic variations and their effects on drug response. PCR allows for the selective amplification of specific DNA regions of interest. PCR is easily scalable, making it suitable for various applications within pharmacogenomics, from research and development to clinical diagnostics. It can be adapted to analyze a wide range of DNA targets and accommodate various sample sizes. PCR technology enables rapid DNA amplification, allowing researchers to process a large number of samples quickly. This efficiency is crucial for high-throughput pharmacogenomics studies and clinical testing, where timely results are essential. PCR can be used for different types of pharmacogenomics analyses, such as genotyping, gene expression profiling, and mutation detection. This versatility makes it a valuable tool for studying various aspects of personalized medicine. PCR has been widely used in molecular biology and genetics for decades. Its well-established protocols and a robust body of knowledge make it a trusted choice in pharmacogenomics research and diagnostics. PCR technology has become more cost-effective over the years, making it accessible to a broader range of research institutions and clinical laboratories. This affordability contributes to its dominance in the market. PCR-based assays have received regulatory approval for use in clinical diagnostics, enhancing their credibility and adoption in pharmacogenomics testing. PCR can be integrated with other technologies and platforms, such as next-generation sequencing (NGS) and microarray analysis, to provide comprehensive pharmacogenomic insights. This integration capability enhances its utility. PCR assays can be customized to target specific genes or genomic regions of interest, allowing researchers to tailor their analyses to the requirements of a particular pharmacogenomics study or clinical application. As personalized medicine gains traction, the demand for pharmacogenomic testing and research continues to grow. PCR technology, with its precision and speed, is well-suited to support the goals of personalized medicine by identifying genetic factors that influence drug response.

Based on region, The Asia Pacific region is experiencing rapid market growth. The region has a well-developed healthcare system, which provides an ideal environment for implementing pharmacogenomics-based approaches. Healthcare providers and institutions have the capacity to integrate pharmacogenomic data into patient care effectively.

Major companies operating in Global Pharmacogenomics Technology Market are:

• QIAGEN N.V.
• GE HealthCare,
• Agilent Technologies, Inc.
• F. Hoffmann-La Roche Ltd
• FOUNDATION MEDICINE, INC.
• Thermo Fisher Scientific Inc.
• Leica Biosystems Nussloch GmBH,
• Pfizer Inc.

Download Free Sample Report

Customers can also request 10% free customization in this report.

“The global pharmacogenomics technology market is poised for significant growth, driven by the convergence of several factors, including increased awareness of personalized medicine, the rising prevalence of chronic diseases, advancements in genomic sequencing, supportive regulatory environments, pharmaceutical industry investments, wider availability of PGx testing, precision medicine initiatives, and the promise of improved patient outcomes and cost savings.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Pharmacogenomics Technology Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapeutic Area (Oncology ( lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others), Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, Others), By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others), By Region & Competition, 2020-2030F”, has evaluated the future growth potential of Global Pharmacogenomics Technology Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Pharmacogenomics Technology Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com